Loading
No insider purchase over the last 90 days. The latest, by AGRI-TECH (INDIA) LTD., was filed 25 Aug 2022.
Nath Bio-Genes (India) Limited: what insiders have been doing
Nath Bio-Genes (India) Limited belongs to the Chemicals sector. Filings by its managers are published through SEBI (PIT + SAST). In the past year (25 October 2025 to 25 October 2026), 3 filings came from 3 insiders.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
With 3 filings in twelve months, the company is quieter than the median of 4 filings across the 1,892 companies we follow on the same exchange. Our records for Nath Bio-Genes (India) Limited go back to 2021, with 9 purchases and 5 sales on the open market in total.
Over the last twelve months, not one insider purchase of Nath Bio-Genes (India) Limited stock was filed. Half of the filings or more reach the SEBI (PIT + SAST) feed on the day of the trade. Until a filing is published, the market cannot know about the trade.
Elsewhere in the same sector, our signals recently picked up insider purchases at Titan and Norske Skog ASA. This summary is built from SEBI (PIT + SAST) disclosures alone and does not predict where the share price will go.
Insider Decl.
29
Thresholds
n/a
Buy Volume
€4M
9 ops. · all time
Sell Volume
€2M
5 ops. · all time
Since the insiders bought
- +8.2%Entry ₹195.40 · Close at T+365 ₹211.40
- +8.2%Entry ₹195.40 · Close at T+365 ₹211.40
- -37.9%Entry ₹225.60 · Close at T+365 ₹140.15
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 6,971 of 26,320 companies
63.4
score / 100
Value67
Quality60
FCF yld-6.0%
Earn yld16%
EV/EBITDA6.1x
ROE6.3%
Gross mgn55%
Net mgn9.4%
Debt/EBITDA2.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
₹135.71
Analyst consensus
Income statement
Revenue₹4.5B
Gross profit₹2.4B55% margin
EBITDA₹655.1M15% margin
Net income₹416.3M9.3% margin
Valuation
PER (trailing)7.4x
P/Book0.4x
Beta0.85
Balance sheet & cash
Market cap₹2.6B
Total debt₹1.4B
Free Cash Flow-₹155.8M
Debt / Equity20%
Profitability & ownership
ROE6.3%
ROA2.9%
% insiders61.7%
% institutions0.0%
Last declaration on 9 January 2026
Declarations29 total
75,271 shares@ ₹10.00100.0% of flowEquity SharesSEBI:c9b3d9acbd853af520c74a1efe9b03182a569225
374 shares@ ₹10.00100.0% of flowEquity SharesSEBI:4c04afac164d19a9e1b3245db624bc050eb4f275
75,645 shares@ ₹10.00100.0% of flowEquity SharesSEBI:0f062e810c0fbdef78af074d1515032b3385fba5
168,800 shares@ ₹211.008.0% of flowEquity SharesSEBI:0a590233e55962bd797ab3dd9364183fda1d283f
168,800 shares@ ₹211.00100.0% of flowEquity SharesSEBI:2fa2b2aea22e92063ba30234c51b6db4dab82de1
311,831 shares@ ₹199.2529.3% of flowEquity SharesSEBI:23fae57e3ab8ebef733c67848717f30b0a76317d
311,831 shares@ ₹199.2514.0% of flowEquity SharesSEBI:d2dc93ad6d8ec62ea11bccb9c1e3ffde3ce32fd7
510,500 shares@ ₹196.0022.9% of flowEquity SharesSEBI:3bb7a243f8e57c8bf1db04d05327c1417db46b1c
510,500 shares@ ₹196.00100.0% of flowEquity SharesSEBI:4299d79d00dc258b1b8d9b6db5341f3d262c9337
170,321 shares@ ₹176.93747.7% of flowEquity SharesSEBI:4185539d7ac475fa6690e1af48515d8a2dafe35f
Canonical exit: 15 Nov 2022 (T+90)
690,000 shares@ ₹180.0568100.0% of flowEquity SharesSEBI:7393226372c26073923ea365ea3cbece7c411769
Canonical exit: 22 Nov 2022 (T+90)
2,798 shares@ ₹188.60290.1% of flowEquity SharesSEBI:b0b29251c28c6791a3477dde145a4677de6430d7
Canonical exit: 31 Aug 2022 (T+90)
100,000 shares@ ₹264.006.5% of flowEquity SharesSEBI:2cb2244bbd1e0fe432a5b663c25613794fe1f7d5
100,000 shares@ ₹264.006.4% of flowEquity SharesSEBI:2935cf04c7f41303f44ed08ef775acda36a2fd7d
100,000 shares@ ₹264.0050.3% of flowEquity SharesSEBI:ca6110b644473ec1783f58d7b67ae3a47d8dcd91
100,000 shares@ ₹264.0049.7% of flowEquity SharesSEBI:2ba836a01d55a1c5fa7110c37b57a47cc1a2859f
332,000 shares@ ₹230.970739.4% of flowEquity SharesSEBI:f842c7eb5a33460ba9d83dd84153b2ba92053186
332,000 shares@ ₹230.970755.7% of flowEquity SharesSEBI:fdef43a0c57fd242eef1dbb734c3fc217f24c3ca
Canonical exit: 19 Jun 2022 (T+90)
290,000 shares@ ₹234.723716.7% of flowEquity SharesSEBI:ec177808d7306020e2b51fe561b9badb8462f1d3
Canonical exit: 21 Jun 2022 (T+90)
285,526 shares@ ₹253.982117.8% of flowEquity SharesSEBI:33033b6a26d248d41cc635bc31d39931309bf2f7
45,000 shares@ ₹261.508.5% of flowEquity SharesSEBI:378cb9f52d32b7a8268a293f19f55c071216fda0
Canonical exit: 28 Feb 2022 (T+90)
45,000 shares@ ₹261.506.0% of flowEquity SharesSEBI:bd0f45011de2b30bf980545e6897b1a515b6b47b
25,000 shares@ ₹536.03716.8% of flowEquity SharesSEBI:d30a224d653b8454efb1ab0df4e9b346b9773438
25,000 shares@ ₹536.03719.7% of flowEquity SharesSEBI:dca06b04befbca88ec86efe0445b7d513ab67a57
Canonical exit: 28 Feb 2022 (T+90)
50,000 shares@ ₹268.01869.8% of flowEquity SharesSEBI:635cf6c2ef03e161a1b85270bde5efc90fc6783b
Canonical exit: 20 Feb 2022 (T+90)
25 of 29 declarations
About Nath Bio-Genes (India) Limited
Nath Bio-Genes (India) Limited is a biotechnology company focused on the development of seeds and agricultural solutions. It primarily operates in the Indian market and concentrates on crop improvement.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
